Search Results - "McSorley, L M"

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer by Browne, I M, McLaughlin, R A, Weadick, C S, O'Sullivan, S, McSorley, L M, Hadi, D K, Millen, S J, Higgins, M J, Crown, J P, Prichard, R S, McCartan, D P, Hill, A Dk, Connolly, R M, Noonan, S A, O'Mahony, D, Murray, C, O'Hanlon-Brown, C, Hennessy, B T, Quinn, C M, Kelly, C M, O'Reilly, S, Morris, P G, Walshe, J M

“…The treatment landscape of Oestrogen receptor-positive (ER-positive) breast cancer is evolving, with declining chemotherapy use as a result of Oncotype DX…”
Get full text

Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland by McSorley, L. M., Tharmabala, M., Al Rahbi, F., McSorley, K., Chew, S., Evoy, D., Geraghty, J. G., Prichard, R. S., Rothwell, J., McCartan, D. P., McDermott, E. W., Keane, M., Kennedy, M. J., O’Reilly, S., Millen, S. J., Crown, J. P., Smyth, L. M., Kelly, C. M., Quinn, C. M., Walshe, J. M.

“…Purpose Results from TAILOR-X suggest that up to 70% of hormone receptor-positive (HR+) node-negative (N0) ESBC patients (pts) may avoid chemotherapy (CT) with…”
Get full text

Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC) by McSorley, L.M., Goggin, C.M., Elhadi, N., O’Dea, P., Sui, J.S.Y., Kelly, D.C., Brady, C., O’Mahony, D.

Get full text

Real-world analysis of clinical and economic impact of 21-gene recurrence score by Chew, S, Evoy, D, Tharmabala, M, McSorley, L. M, Geraghty, J. G, McSorley, K, Al Rahbi, F

“…Purpose Results from TAILOR-X suggest that up to 70% of hormone receptor-positive (HR+) node-negative (N0) ESBC patients (pts) may avoid chemotherapy (CT) with…”
Get full text

Real-world analysis of clinical and economic impact of 21-gene recurrence score in Ireland by McSorley, L. M, Tharmabala, M, Al Rahbi, F, McSorley, K, Chew, S, Evoy, D, Geraghty, J. G

“…Purpose Results from TAILOR-X suggest that up to 70% of hormone receptor-positive (HR+) node-negative (N0) ESBC patients (pts) may avoid chemotherapy (CT) with…”
Get full text

64PTiming of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC) by McSorley, L M, Goggin, C M, Elhadi, N, O’Dea, P, Sui, J S Y, Kelly, D C, Brady, C, O’Mahony, D

Get full text